Table 1.
Participant characteristics.
| Variable | Participants (N=39) | ||
| Age (years), mean (SD) | 58.18 (10.60) | ||
| Race, n (%) | |||
|
|
Caucasian | 30 (77) | |
|
|
African American | 7 (18) | |
|
|
Asian | 1 (3) | |
|
|
Unreported | 1 (3) | |
| Ethnicity, n (%) | |||
|
|
Non-Hispanic | 38 (97) | |
|
|
Hispanic | 1 (3) | |
| Marital status, n (%) | |||
|
|
Married | 26 (67) | |
|
|
Single | 7 (18) | |
|
|
Divorced | 5 (13) | |
|
|
Widowed | 1 (3) | |
| Education level, n (%) | |||
|
|
High school | 3 (8) | |
|
|
College graduate | 16 (41) | |
|
|
Postgraduate school | 20 (51) | |
| Breast cancer stage, n (%) | |||
|
|
0 | 2 (5) | |
|
|
I | 14 (36) | |
|
|
II | 17 (44) | |
|
|
III | 6 (15) | |
| Surgerya, n (%) | |||
|
|
Mastectomy | 22 (56) | |
|
|
Lumpectomy | 15 (39) | |
| Radiationa, n (%) | 27 (69) | ||
| Chemotherapya, n (%) | 23 (59) | ||
| AIb type, n (%) | |||
|
|
Letrozole | 6 (15) | |
|
|
Anastrozole | 21 (54) | |
|
|
Exemestane | 9 (23) | |
|
|
Other | 3 (8) | |
| AI medication duration (years), n (%) | |||
|
|
≤1 | 12 (31) | |
|
|
1-3 | 12 (31) | |
|
|
3-6 | 12 (31) | |
|
|
Unreported | 3 (8) | |
aTreatment options do not add up to 39 due to individual treatment choices.
bAI: aromatase inhibitor.